During the high profile JPMorgan Healthcare Conference, Motley Fool health care bureau chief Brenton Flynn took a moment to look back at some of the interesting things he observed. In this segment of the video, he discusses a prostate-cancer-focused biotech Medivation (NASDAQ:MDVN) and its presentation -- and three potential share price catalysts.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
